New Testing Processes

In response to new clinical research that shows a definite risk for the development of obstructive airways disease leading to a diagnosis of chronic obstructive pulmonary disease in current or ex-smokers who are heterozygotes for α1-antitrypsin deficiency, Alpha1 Center has modified its testing processes to ensure that heterozygotes are detected. This change was effective on February 1, 2014.

 

 

Patients Tested

273,762

               ...and Counting!

 
Alpha-1 Access Find Test
Results Here

For Healthcare Practitioners Only

Information
For Patients

Learn more about Alpha1Center